The prognostic value of TCF1+CD8+T in primary small cell carcinoma of the esophagus

Lin Ma1,2 | Lijun Sun3 | Kaikai Zhao4 | Zhengxin Dong5 | Zhaoqin Huang1,6 | Xiangjiao Meng1,2

1Cheeloo College of Medicine, Shandong University, Jinan, China
2Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
3Department of Thoracic Tumor, Affiliated Hospital of Jining Medical University, Jining, China
4Department of Radiation Oncology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China
5School of Electronics Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai, China
6Department of Radiology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China

Correspondence
Zhaoqin Huang, Department of Radiology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250117, China.
Email: devin813@163.com
Xiangjiao Meng, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250117, China.
Email: mengxiangjiao@126.com

Funding information
National Natural Science Foundation of China, Grant/Award Number: 81972796 and 81972863 Natural Science Foundation of Shandong Province, Grant/Award Number: ZR2019MH010 and ZR2020MH289.

Abstract
TCF1+CD8+T cells are reported to exhibit stem-like properties with the ability to self-renew and differentiate into terminal effector T cells (TCF1-CD8+T cells) to enhance antitumor response. Previous studies indicated that TCF1+CD8+ tumor-infiltrating lymphocytes (TILs) are related to response to immunotherapy. However, their role in predicting prognosis for patients with primary small cell carcinoma of the esophagus (PSCCE) remains unclear. In this study, the expression of TCF1+CD8+T was analyzed by multiplex fluorescein immunohistochemistry in tumor tissues of 79 patients with PSCCE. High infiltration of TCF1+CD8+T cells had longer overall survival (OS) than low infiltration (P = .009, hazard ratio [HR] = 0.506). High TCF1+CD8/CD8 ratio (>21%) showed superior OS compared with low ratio (≤21%) (P < .001, HR = 0.394). In the validation set (n = 20), the prognostic value of TCF1+CD8+T cells on OS was also verified. TCF1+CD8+T cells are strong prognostic predictors.

KEYWORDS
prognosis, PSCCE, stem-like, TCF1, tumor microenvironment

Abbreviations: ACT, adoptive T cell therapy; AUC, the area under the curve; HLA, human leukocyte antigen; ICI, immune checkpoint inhibitor; LCMV, lymphocytic choriomeningitis virus; OS, overall survival; PFS, progression-free survival; PSCCE, primary small cell carcinoma of the esophagus; ROC, receiver-operating characteristic; IHC, immunohistochemistry; TIL, tumor-infiltrating lymphocyte; NK, natural killer.

This work was carried out at Shandong University and Shandong Cancer Hospital and Institute Affiliated to Shandong First Medical University. (The present address of Lijun Sun and Zhengxin Dong is different from that where the work was carried out).

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Primary small cell carcinoma of the esophagus (PSCCE) is one of the malignancies in the world and is characterized by low incidence, high aggressiveness, and poor prognosis. Previous studies indicated that the abundance of CD8+ T cells is associated with clinical benefits in many cancers, such as esophageal squamous cell carcinomas or adenocarcinomas and non-small cell lung cancer. However, CD8+ tumor-infiltrating lymphocytes (TILs) represent a highly heterogeneous population, consisting of distinct subpopulations. It is urgent to identify the composition of CD8+ TILs and the subpopulation with antitumor immune response.

An effective immune response depends on progenitor cells capable of self-renewal and proliferation. In chronic lymphocytic choriomeningitis virus (LCMV) infection and cancer, T cells that express TCF-1 are defined as stem-like T cells. Transcription factor T-cell factor 1 (TCF-1), encoded by TCF-7, is a critical transcription factor of T lymphocyte cell development. TCF-1 silencing causes T progenitor cells to lose their self-renewing ability and means irreversible differentiation of effector T cells, as confirmed by mouse models. In addition to persisting in tertiary lymphoid structures, the TCF1+ population is also observed in tumor area. Recent studies indicated that TCF1+CD8+TILs exhibit stem-like properties with the ability to self-renew and differentiate into terminal effector T cells (TCF1-CD8+T cells) to maintain antitumor response. Moreover, TCF1+CD8+T cells can undergo massive expansion in response to anti-PD-1 treatment. The high infiltration of TCF1+CD8+TILs has been shown to be associated with prolonged progression-free survival (PFS) and overall survival (OS) in melanoma patients receiving checkpoint blockade. Moreover, human leukocyte antigen (HLA) class 1 (HLA-I) downregulation is an immune escape mechanism in tumors. It plays an important role in the antitumor effect of CD8+ T cells. The survival association of combined HLA-I expression and stem-like CD8+T requires further exploration.

In this study, we performed a quantitative analysis of intratumoral stem-like T cells, evaluated its prognostic value, and assessed its association with HLA-I.

2 MATERIALS AND METHODS

This retrospective study has been approved by the Ethics Review Board of Shandong Cancer Hospital and Institute and Shandong Provincial Hospital Affiliated to Shandong University and it conforms to the provisions of the Declaration of Helsinki. This study was a retrospective analysis and did not require informed consent from patients.

2.1 Human samples

We collected tumor tissue from 79 patients diagnosed with PSCCE and treated in Shandong Cancer Hospital and Institute or Shandong Provincial Hospital. Of the total 79 patients, 39 patients had undergone surgery, and 40 patients had received chemotherapy or chemotherapy combined with radiotherapy. In addition, we enrolled 20 patients in the validation set. Information on tumor size, infiltration depth, node metastatic status, histological grade, TNM classification, and proliferative activity (Ki-67) was collected.

2.2 Immunohistochemistry staining

Paraffin-embedded tumor tissues were cut to obtain serial sections (4 µm thick). Slides hatched at 65°C for 1 hour were deparaffinized and rehydrated in xylene solution and ethanol series. Antigen retrieval was performed in saline citrate buffer. After heating, the slides were cooled to room temperature and rinsed briefly with phosphate-buffered saline (PBS). Endogenous peroxidase activity was neutralized by peroxidase blocking for 15 minutes. Then, the slides were washed with PBS and treated with Protein Block for 15 minutes. Next, the slides were incubated with HLA-I antibody (Abcam, ab70328) overnight at 4°C. Then, cleaned slides were incubated with Novolink DAB substrate buffer and stained with hematoxylin, dehydrated, and placed on cover slips.

The expression levels of HLA-I were assessed by a pathologist who was unaware of the patient's clinical outcomes. The percentage of staining positive cells was 0% (0), 1%-10% (1), 11%-30% (2), 31%-66% (3), 67%-80% (4), and >80% (5). Intensity score: 0, no staining; 1, weak; 2, gentle; 3, strong. The scale and intensity scores were added to get an overall score (range 0-8). The expression of HLA-I was defined as high when the total score was ≥5.

2.3 Multiplex fluorescence immunohistochemistry

Tissue sections were stained using the OPAL 7-COLOR MANUAL immunohistochemistry (IHC) kit (Cat. NEL81001KT, Akoya). Paraffin-embedded tumor tissues were cut to obtain serial sections (4 µm thick). Slides hatched at 65°C for 1 hour were deparaffinized and rehydrated in xylene solution and ethanol series. Antigen retrieval was performed in saline citrate buffer (pH 6.0) at 95°C for 20 minutes. Then, the slides were placed in 0.1% Triton X100 PBS (PBST) and rinsed for 15 minutes. After 1 hour of blocking, rinse slides with PBST for 15 minutes. Then, slides were incubated with the CD4 antibody (Novus, NBP1-19371) for 2 hours at room temperature. After 15 minutes of flushing, slides were incubated with Opal Polymer HRP for 10 minutes. Next, after flushing, Opal fluorochrome was added to the slides and incubated for 10 minutes. The antigen retrieval operation and blocking were repeated, the slides were incubated with CD8 antibody (Abcam, ab199016) and TCF1 antibody (CST, C63D9) in sequence, and finally mounted with DAPI (Abcam, ab104135).

2.4 Digital image acquisition and analysis

The stained slides were scanned and analyzed using the TissueFAXS slide scanning system based on a Zeiss Axio Imager Z2.
epifluorescence microscope (Tissue Gnostics). Image acquisition was performed using the StrataQuest software (TissueGnostics). The software’s workflow and data display for image cytometry of tissue sections, tissue, and cell cultures is similar to flow cytometry. StrataQuest provides cellular data in dot plots to show parameters of cell structure, thus providing analysis of cell phenotypes and tissue cytometry. The software creates scatterplots that visualize positive and negative cells through a gating function. A low magnification scan is used to determine the position of tissue on the slide. High magnification images were used for all downstream analyses. The resulting image is exported as a full-resolution TIFF file for each dye channel’s grayscale. The tiled image is reconstructed by image mosaic algorithm. The software identified cells by recognizing DAPI-stained nuclei based on thresholds set for intensity. Then, the staining intensity of the channels associated with each cell was measured. Positive cells are determined by a threshold set by the intensity of the detection of signal intensity (Figure 1).

HE staining was used to determine the intratumoral area (Figure 1). Five intratumoral regions were randomly selected and analyzed. The cell counts and the percentage of positive cells out of the total number of cells (% positive cells/all nucleated cells) were measured using the TissueQuest analysis platform. Time-dependent receiver-operating characteristic (ROC) curves were used to determine optimal cutoff values and corresponding sensitivities and specificities.

3.1 | Patient characteristics

We detected the expression of CD8+ T cells, TCF1+ T cells, TCF1+CD4+ T cells, and TCF1+CD8+ T cells in tumor tissues of 79 patients with PSCCE. The percentage of the above indicators in all the cells of tumor tissue were used to define expression levels. As far as we know, the cutoff value of the above indicators and the

**FIGURE 1** Localization and cytometric quantitation of scanned images. Nuclear segmentation (green outline) using DAPI staining identifies individual cells (C). The membrane mask (red ring) is the quantification of membrane markers for each cell (D, CD8; E, TCF1; F, CD4). Scatter plots were generated by StratQuest image analysis software based on the average staining intensity of each channel (G, H). Each dot represents one cell. The dividing line in the figure represents the intensity threshold to take into account the positive signal in each channel. Scale bars: 50 µm (A and B) and 20 µm (C, D, E, and F). CD4 (green), CD8 (yellow), TCF1 (red), and DAPI (blue).
TCF1+CD8/CD8 ratio in PSCCE are not yet clear. We used time-dependent ROC curves to determine the optimal cutoff value. The area under the curve (AUC) for CD8+T cells, TCF1+CD8+T, and TCF1+CD8/CD8 ratio was 0.633, 0.650, and 0.674, respectively (Figure 2E, F, G). The optimal cutoff of CD8+T cells, TCF1+CD8+T cells, and TCF1+CD8/CD8 ratio was 0.93% (sensitivity 49.2%, specificity 64.3%), 0.34% (sensitivity 72.3%, specificity 42.9%), and 21% (sensitivity 69.2%, specificity 89%), respectively. The AUC values for CD4+T cells, TCF1+T cells, and TCF1+CD4+T cells indicated poor discriminatory power (near 0.5). The mean values of CD8+T cells, TCF1+CD8+T cells, and TCF1+CD8/CD8 ratio are 1.30%, 0.29%, and 17%, respectively. The median values of CD8+T cells, TCF1+CD8+T cells, and TCF1+CD8/CD8 ratio are 0.97%, 0.13%, and 15%, respectively. TCF1+CD8+T had low expression in 55 (70%) patients, and HLA-I had low expression in 40 (51%) patients (Figure 2).

3.2 | Correlation between TCF1+CD8+T cells and clinicopathological characteristics

Details of the correlation are summarized in Table 1. The level of CD8+ T cells has no correlation with age, sex, alcohol, smoking history, Ki-67 level, and neuron-specific enolase (NSE) level, but it has correlation with T stage (P = 0.045), lymph node status (P = 0.036), metastatic status (P = 0.001), or TNM stage (P = 0.004). Moreover, patients with T1-T2 stage (P = 0.002), N0-N1 status (P = 0.011), or without metastasis (P = 0.013) had higher TCF1+CD8/CD8 ratio (Table 1, Figure 3). In brief, these results demonstrate that CD8+T cells and TCF1+CD8+T cells are related to tumor development, progression, and metastasis of lymph nodes.

3.3 | CD8+T cells and TCF1+CD8+T cells infiltration as prognostic biomarkers

Patients with high infiltration of CD8+T cells and TCF1+CD8+T cells have longer median OS (mOS, 25 vs 16 months, P = 0.013, hazard ratio [HR] = 0.555; 31 vs 17 months, P = 0.009, HR = 0.506; respectively; Figure 4A, B). We also proved that high TCF1+CD8/CD8 ratio showed superior OS compared with low ratio (mOS, 31 vs 16 months, P < 0.001, HR = 0.394, Figure 4C). Furthermore, we compared the impact of CD8+T and TCF1+CD8+T on the prognosis. In patients with high CD8+T infiltration, high TCF1+CD8/CD8 ratio showed better OS (mOS, 32 vs 19 months, P = 0.042, HR = 0.511 Figure 4D). We found that the OS rate decreased with

![Figure 2](https://example.com/f2.png)
the increase of TNM staging (Figure 4E, \( P < .001 \)), suggesting the prognostic value of TNM staging for PSCCE. We also evaluated the prognostic value of combined \( \text{TCF1} + \text{CD8} \) and TNM stage. Although not statistically significant, in numerical terms, high \( \text{TCF1} + \text{CD8} \) prolonged median OS in patients with stage I-II and stage III-IV (28.5 vs 35 months; 15 vs 22 months; Figure 4F, G). We verified the survival association of \( \text{TCF1} + \text{CD8} \) in the validation set. In order to validate significant results, it was also evaluated in the validation set (\( n = 20 \)). Patients with high infiltration of \( \text{TCF1} + \text{CD8} \) showed longer OS (mOS, 62 vs 18 months, \( P = .021 \); Figure 4K).

## 3.4 | Effect of combined \( \text{TCF1} + \text{CD8} \) and HLA-I expression

We also assessed the significance of \( \text{TCF1} + \text{CD8} \) cells expression in subgroups classified by HLA-I expression. The expression of HLA-I was not associated with OS (\( P = .962 \)). When HLA-I expression was low, the expression of \( \text{TCF1} + \text{CD8} \) was not related to OS (mOS, 17 vs 31 months, \( P = .615 \)). When HLA-I was highly expressed, the expression of \( \text{TCF1} + \text{CD8} \) was related to better OS (mOS, 16 vs 32 months, \( P = .008 \); Figure 4J).

## 3.5 | Prognostic factors in PSCCE by multivariate analysis

We analyzed the prognostic value by cox regression model, as shown in Table 2. The univariate analysis showed that T stage (\( P = .006 \)), lymph node status (\( P = .002 \)), metastatic status (\( P < .001 \)), \( \text{CD8} + \text{T} \) cells (\( P = .016 \)), \( \text{TCF1} + \text{CD8} + \text{T} \) (\( P = .012 \)), and \( \text{TCF1} + \text{CD8}/\text{CD8 ratio} \) (\( P < .001 \)) were correlated with OS. The multivariate analysis showed that metastatic status (\( P = .002 \)), T stage (\( P = .064 \)), and \( \text{TCF1} + \text{CD8}/\text{CD8 ratio} \) (\( P = .004 \)) were correlated with OS.

These results indicated that \( \text{CD8} + \text{T} \), \( \text{TCF1} + \text{CD8} + \text{T} \), and \( \text{TCF1} + \text{CD8}/\text{CD8 ratio} \) can predict the prognosis of PSCCE. Notably, the ratio of \( \text{TCF1} + \text{CD8} \) and \( \text{CD8} \) T cells might have a strong predictive value when compared with other markers.

## 4 | DISCUSSION

Central memory \( \text{CD8} + \text{T} \) cells, the earliest developmental stage of memory T cells, could provide sustained responses to maintain antitumor power efficacy.\(^{13}\) \( \text{TCF1} \) is a major regulator of the stem-like properties of central memory \( \text{CD8} + \text{T} \) cells.\(^{13}\) The infiltration of \( \text{TCF1} + \text{CD8} + \text{T} \) cells in tumor tissues has been reported in melanoma.

### Table 1: The clinicopathological characteristics of primary small cell carcinoma of the esophagus (PSCCE) Patients

| Variables     | CD8+T Low | CD8+T High | P    | TCF1+CD8T Low | TCF1+CD8T High | P    | TCF1+CD8/CD8 Low | TCF1+CD8/CD8 High | P    |
|---------------|-----------|------------|------|---------------|---------------|------|-----------------|------------------|------|
| Age           | <60       | 20         | 18   | .320          | 27            | 11   | .790            | 24               | 14   | .631 |
|               | ≥60        | 17         | 24   |               | 28            | 13   |               | 28               | 13   |      |
| Gender        | Male      | 10         | 8    | .399          | 15            | 3    | .150            | 14               | 4    | .212 |
|               | Female    | 27         | 34   |               | 40            | 21   |               | 38               | 23   |      |
| Alcohol abuse | NO        | 20         | 18   | .320          | 30            | 8    | .083            | 26               | 12   | .639 |
|               | YES       | 17         | 24   |               | 25            | 16   |               | 26               | 15   |      |
| T stage       | T1-T2     | 8          | 18   | .045          | 14            | 12   | .033            | 11               | 15   | .002 |
|               | T3-T4     | 29         | 24   |               | 41            | 12   |               | 41               | 12   |      |
| N stage       | N0-N1     | 22         | 34   | .036          | 36            | 20   | .108            | 32               | 24   | .011 |
|               | N2-N3     | 15         | 8    |               | 19            | 4    |               | 20               | 3    |      |
| M stage       | M0        | 24         | 40   | .001          | 42            | 22   | .199            | 38               | 26   | .013 |
|               | M1        | 13         | 2    |               | 13            | 2    |               | 14               | 1    |      |
| Ki-67         | Low       | 13         | 14   | .521          | 19            | 8    | .535            | 17               | 10   | .993 |
|               | High      | 14         | 21   |               | 22            | 13   |               | 22               | 13   |      |
pediatric glioma, and prostate and bladder tumors.\textsuperscript{9,12,15} Previous studies indicated that TCF1-TIL is positively correlated with tumor regression in melanoma.\textsuperscript{22} In this study, we performed a quantitative analysis of intratumoral TCF1-CD8+ T cells by using multiplex fluorescence IHC. We proved that the infiltration of TCF1-CD8+ T cells is a positive prognostic biomarker.

Stem-like T cells could stimulate persistent antitumor immune response, which is critical for adoptive T cell therapy (ACT), tumor vaccines, and immune checkpoint inhibitor (ICI) treatment. Sri Krishna et al.\textsuperscript{23} demonstrated that stem-like TILs mediate ACT response against human tumor. A preclinical study also indicated that antitumor response of tumor vaccines depends on stem-like TILs.\textsuperscript{15} Patients with melanoma who respond to anti-PD-1 treatment have high stem-like CD8+ T infiltration, and the higher the infiltration, the longer the PFS and OS.\textsuperscript{16,22} Similarly, our results showed that high CD8+ TILs and TCF1-CD8+ TILs are positively related to longer OS. We also demonstrated that among patients with high CD8+ TILs, patients with high TCF1-CD8/CD8 ratio were more likely to obtain better OS. High TCF1-CD8/CD8 ratio was also related to T stage, lymph node metastasis, distant metastasis, and TNM stage, which shows TCF1-CD8/CD8 ratio might be a strong factor in tumor control and metastasis. In addition, we also discussed the prognostic value of combined TNM stage and TCF1-CD8+ T because TNM stage is a powerful prognostic factor. For patients with the same TNM stage, high TCF1-CD8+ T numerically prolonged OS. Besides, although CD4+ T cell is involved in the activation of CD8+ T cells,\textsuperscript{24} we did not find any relationship between CD4+ TIL or TCF1-CD4+ TIL and survival benefits.

HLA-I is necessary for the recognition of tumor cells by CD8+ T cells. The relationship between HLA-I expression and survival time has complex results. Previous studies reported that HLA-I expression was associated with better survival in pancreatic cancer, non–small cell lung cancer, and esophageal squamous cell carcinoma, while it is associated with poor prognosis in gastric cancer.\textsuperscript{25–28} Tumor cells could evade cytotoxic CD8+ T cells by downregulating HLA-I expression.\textsuperscript{29} On the contrary, HLA-I, as an inhibitory receptor of natural killer (NK) cells, promotes tumor escape in the case of low HLA-I.\textsuperscript{30,31} In this study, HLA-I expression was not significantly associated with survival. Patients were classified into two groups based on HLA-I expression to investigate the impact of TCF1-CD8+ T cells. In the context of high HLA-I expression, patients with high TCF1-CD8+ T cells...
**FIGURE 4** Kaplan-Meier survival analyses. Intratumoral TILs (CD8+, TCF1+CD8+, and TCF1+CD8/CD8 ratio) could predict survival benefits (A, B, C, and D). E, F, G, H, and I, Kaplan-Meier survival analysis of combined TCF1+CD8+ and TNM stage. In the case of high HLA-I expression, high TCF1+CD8+ was associated with better overall survival (OS) (J). K and L, Kaplan-Meier survival analysis for OS in the validation set.

**TABLE 2** Univariate analyses and multivariate analysis of prognostic markers for overall survival (OS) in primary small cell carcinoma of the esophagus (PSCCE)

| Variable             | Univariate analysis | Multivariate analysis |
|----------------------|---------------------|-----------------------|
|                      | HR (95% CI)         | P                     | HR (95% CI)         | P                     |
| Age                  |                     |                       |                      |                       |
| <60 vs ≥60           | 0.871 (0.533-1.424) | .581                  |                      |                       |
| Gender               |                     |                       |                      |                       |
| Male vs female       | 1.120 (0.838-1.496) | .444                  |                      |                       |
| Alcohol abuse        |                     |                       |                      |                       |
| No vs yes            | 1.104 (0.678-1.799) | .690                  |                      |                       |
| Ki-67 level          |                     |                       |                      |                       |
| <80 vs <80           | 1.321 (0.748-2.334) | .337                  |                      |                       |
| NSE level            |                     |                       |                      |                       |
| ≤16.3 vs >16.3       | 1.296 (0.682-2.464) | .429                  |                      |                       |
| T stage              |                     |                       |                      |                       |
| T1-T2 vs T3-T4       | 2.136 (1.250-3.651) | .006                  | 1.713 (0.970-3.028)  | .064                  |
| N stage              |                     |                       |                      |                       |
| N1-N2 vs N3-N4       | 2.477 (1.410-4.351) | .002                  |                      |                       |
| M stage              |                     |                       |                      |                       |
| M0 vs M1             | 4.734 (2.400-9.335) | <.001                 | 3.062 (1.527-6.138)  | .002                  |
| CD8+TILs             |                     |                       |                      |                       |
| Low vs high          | 0.545 (0.332-0.893) | .016                  |                      |                       |
| TCF1+CD8+TILs        |                     |                       |                      |                       |
| Low vs high          | 0.493 (0.284-0.857) | .012                  |                      |                       |
| TCF1+CD8/CD8         |                     |                       |                      |                       |
| Low vs high          | 0.366 (0.213-0.627) | <.001                 | 0.439 (0.249-0.775)  | .004                  |

Abbreviations: CI, confidence interval; HR, hazard ratio; NS, not significant; NSE, neuron-specific enolase; OS, overall survival.
were associated with better clinical benefits. In the case of low HLA-I expression, TCF1+CD8+ T was not significantly associated with prognosis. This may be related to the fact that the limited loss of HLA-I weakened the antigen recognition and thus attenuated the immune response.

Stem-like CD8+ T cells have been reported to exist near the antigen-presenting cells (APCs) gathering area. TCF1+PD-1+CD8+ T cells are also observed in tertiary lymphoid structures or “specialized vascular niches.” Distribution characteristics of TCF1+CD8+ T might facilitate tumor-specific CD8+ T cells to populate into the tumor to maintain durable antitumor response. Therefore, analysis of the spatial distribution characteristics of TCF1+CD8+ T requires further study.

We localized stem-like T cells by fluorescent multiplex immunohistochemistry and quantified them by software based on intelligent algorithms, which greatly improves the efficiency compared with traditional IHC that requires a pathologist to score. Furthermore, it should be noted that we also have some limitations. PSCCE is characterized by low incidence and poor prognosis. Only 99 patients were enrolled in our study, and 20 of them were enrolled in the validation set.

In summary, we identified the abundance of intratumoral stem-like T cells (TCF1+CD8+ T) in PSCCE. High infiltration of TCF1+CD8+ T cells is related to better clinical outcomes. TCF1+CD8+ T cells are strong and independent prognostic predictors.

ACKNOWLEDGMENTS
This paper was funded by the National Natural Science Foundation of China (No.81972796 and 81972863) and the Natural Science Foundation of Shandong (No. ZR2019MH010 and ZR2020MH289).

CONFLICT OF INTEREST
The authors have no conflict of interest.

ORCID
Xiangjiao Meng https://orcid.org/0000-0001-7380-5510

REFERENCES
1. Ji A, Jin R, Zhang R, Li H. Primary small cell carcinoma of the esophagus: progression in the last decade. Ann Transl Med. 2020;8(7):502.
2. Fridman WH, Galon J, Pagès F, Tartour E, Sautès-Fridman C, Kroemer G. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res. 2011;71(17):5601-5605.
3. Dieci MV, Criscitiello C, Gobhar A, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014;25(3):611-618.
4. Horne ZD, Jack R, Gray ZT, et al. Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. J Surg Res. 2011;171(1):1-5.
5. Schumacher K, Haensch W, Röeffzaad C, Schlag PM. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res. 2001;61(10):3932-3936.
6. Simoni Y, Becht E, Fehlings M, et al. Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018;557(7706):575-579.
7. He R, Hou S, Liu C, et al. Follicular CXCR5+ expressing CD8(+) T cells curtail chronic viral infection. Nature. 2016;537(7620):412-428.
8. Utzschneider DT, Charmoy M, Chennupati V, et al. T Cell factor 1-expressing memory-like CD8(+) T cells sustain the immune response to chronic viral infections. Immunity. 2016;45(2):415-427.
9. Jansen CS, Prokhnevskva N, Master VA, et al. An intra-tumoural niche maintains and differentiates stem-like CD8 T cells. Nature. 2019;576(7787):465-470.
10. Germar K, Dose M, Konstantinou T, et al. T-cell factor 1 is a gatekeeper for T-cell specification in response to notch signaling. Proc Natl Acad Sci USA. 2011;108(50):20060-20065.
11. Lin WW, Nish SA, Yen B, et al. CD8(+) T lymphocyte self-renewal during effector cell determination. Cell Rep. 2016;17(7):1773-1782.
12. Robinson MH, Vasquez J, Kaushal A, et al. Subtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma. J Immunother Cancer. 2020;8(2):e001066.
13. Pais Ferreira D, Silva JG, Wyss T, et al. Central memory CD8(+) T cells derive from stem-like Tcf7(+) effector cells in the absence of cytotoxic differentiation. Immunity. 2020;53(5):985-1000 e11.
14. Raghu D, Xue HH, Mielke LA. Control of lymphocyte fate, infection, and tumor immunity by TCF-1. Trends Immunol. 2019;40(12):1149-1162.
15. Siddiqui I, Schaeuble K, Chennupati V, et al. Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity. 2019;50(1):195-211 e10.
16. Miller BC, Sen DR, Al Abosy R, et al. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019;20(3):326-336.
17. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunosellection and immunosubversion. Nat Rev Immunol. 2006;6(10):715-727.
18. Miller TJ, Anyaegbu CC, Lee-Pulman TF, Spalding LJ, Platell CF, McCoy MJ. PD-L1+ dendritic cells in the tumor microenvironment correlate with good prognosis and CD8+ T cell infiltration in colon cancer. Cancer Sci. 2021;112(3):1173-1183.
19. Han SJ, Reis G, Kahanbash G, et al. Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. J Neurooncol. 2016;130(3):543-552.
20. Mattox AK, Lee J, Westra WH, et al. PD-1 expression in head and neck squamous cell carcinomas derives primarily from functionally anergic CD4(+) TILs in the presence of PD-L1(+) TAMs. Cancer Res. 2017;77(22):6365-6374.
21. Graef P, Buchholz VR, Stemberger C, et al. Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells. Immunity. 2014;41(1):116-126.
22. Sade-Feldman M, Yizhak K, Bjorgaard SL, et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell. 2018;175(4):998-1013.e20.
23. Krishna S, Lowery FJ, Copeland AR, et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human melanoma. Nature. 2019;569(7755):183-194.
24. Kanev K, Wu M, Drews A, et al. Proliferation-competent Tcf1+ CD8 T cells in dysfunctional populations are CD4 T cell help independent. Proc Natl Acad Sci USA. 2019;116(40):20070-20076.
25. Imai D, Yoshizumi T, Okano S, et al. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer. Cancer Med. 2017;6(7):1614-1626.
26. Kikuchi E, Yamazaki K, Torigoe T, et al. HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. *Cancer Sci*. 2007;98(9):1424-1430.

27. Mizukami Y, Kono K, Maruyama T, et al. Downregulation of HLA class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma. *Br J Cancer*. 2008;99(9):1462-1467.

28. Ueda Y, Ishikawa K, Shiraishi N, Yokoyama S, Kitano S. Clinical significance of HLA class I heavy chain expression in patients with gastric cancer. *J Surg Oncol*. 2008;97(5):451-455.

29. Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL. 2011: the immune hallmarks of cancer. *Cancer Immunol Immunother*. 2011;60(3):319-326.

30. Campbell KS, Purdy AK. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. *Immunology*. 2011;132(3):315-325.

31. Long EO. Tumor cell recognition by natural killer cells. *Semin Cancer Biol*. 2002;12(1):57-61.

32. Held W, Siddiqui I, Schaebule K, Speiser DE. Intratumoral CD8(+) T cells with stem cell-like properties: implications for cancer immunotherapy. *Sci Transl Med*. 2019;11(515):eaay6863.

How to cite this article: Ma L, Sun L, Zhao K, Dong Z, Huang Z, Meng X. The prognostic value of TCF1+CD8+ T in primary small cell carcinoma of the esophagus. *Cancer Sci*. 2021;112:4968–4976. [https://doi.org/10.1111/cas.15167](https://doi.org/10.1111/cas.15167)